LONA

LeonaBio is a clinical-stage biopharma that, by its own admission, has "not generated any revenues related to our drug products since inception" and won't for "a number of years." The income statement confirms it: five straight years of deepening losses (-$54.9M in FY2021 to -$106M in FY2025), an operating loss of -$102M, and an accumulated deficit of -$512M. There is no business here yet — only two clinical programs (lasofoxifene, an in-licensed Phase 3 SERM for ESR1-mutated metastatic breast cancer acquired only in December 2025, and ATH-1105, a Phase 2-ready ALS candidate). Value is entirely contingent on binary trial readouts and eventual FDA approval, which the MD&A explicitly frames as uncertain.

The balance sheet is thin and deteriorating. Cash of $69.3M against operating cash burn of -$45.7M implies only ~1.5 years of runway, and that burn will rise as the registrational Phase 3 advances. Total liabilities ballooned +361.8% YoY to $64.4M (current liabilities +261.7%), driving liabilities/equity to 2.32x and cutting stockholders' equity -38% to just $27.8M. ROE is a meaningless -380%. The R&D line falling -75.2% to $17.5M is not discipline — for a clinical-stage name it signals a pipeline in transition (the lasofoxifene deal only just closed), not durable cost control.